| Name | Title | Contact Details |
|---|
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.
Complexity in our healthcare system is standing in the way of people accessing care they need. It`s also driving crippling costs. We utilize our deep expertise in influencing consumer behavior to drive better healthcare decisions, increase quality and decrease costs.
Bethesda is a nonprofit Christian organization that provides homes and other services for people with intellectual and developmental disabilities. Bethesda`s over 3,000 dedicated employees, volunteers and direct support professionals provide residential and supported-living services and religious assistance to nearly 2,000 adults with developmental disabilities. For more than 110-years, Bethesda has been devoted to the mission of providing person-centered care and support for people with intellectual and developmental disabilities.
Precedence is a Rock Island, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Soft infotech is a Clifton, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.